|
The device is used to provide supplemental oxygen to patient with compromised respiratory function.It is not intended to be used as a life sustaining device.It was stated that the device was in conserve mode, which means the device producing a bolus of supplemental oxygen as the patient inhales.If the patient's breathing was shallow after the syncopal episode, there may not have been enough negative pressure for the device to deliver the oxygen at conserve mode.Once the device oxygen flow function was switched to continuous flow a steady flow of oxygen was delivered to the patient.It was stated that the patient was easily aroused and regained consciousness spontaneously with no medical intervention.These factors conclude that the patient did not suffer a loss of consciousness, but rather a syncopal episode.Syncopal episodes are a temporary loss of consciousness and posture, described as "fainting" or "passing out".It usually related to temporary insufficient blood flow to the brain.It most often occurs when the blood pressure is too low (hypotension) and the heart does not pump a normal supply of oxygen to the brain.If the patient had lost consciousness due to decreased oxygen to the brain (hypoxia), the patient would have needed more aggressive respiratory treatment than just simply switching the device to continuous flow mode.Syncope can be caused by neurological disorder, orthostatic hypotension or a side effect of medications.It can be concluded that the patient's temporary loss of consciousness was caused by some factor other than the amount of oxygen given or not given by the device.With the information provided, there is insufficient evidence to determine a causal relationship between the alleged in the complaint and the patient's syncopal episode; however, because a patient reportedly had a syncopal episode associated with an inovo device, the event was reported to the fda.The device has not yet been received for testing.Inovo, inc.Will submit a supplemental report if the device is received and after inovo, inc.Service/repair facility concludes its investigation.Note that this mdr was previously submitted on 02/03/2017 and is being re-submitted because it was not fully processed or received by fda due to an error.
|